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Abstract
Ovariancancerhasadisproportionatelyhighmortalityratebecausepatientstypicallypresentwithlate-
stage metastatic disease. The vast majority of these deaths are from high-grade serous carcinoma.
Recent studies indicate that many of these tumors arise from the fallopian tube and subsequently
metastasize to the ovary. This may explain why such tumors have not been detected at early stage as
detection efforts have been focused purely on the ovary. In keeping with this leap in understanding
otheradvancessuchasthedevelopmentofex-vivomodelsandimmortalizationofhumanfallopiantube
epithelial cells, and the use of integrated genomic analyses to identify hundreds of novel candidate
oncogenes and tumor suppressors potentially involved in tumorigenesis now engender hope that we
can begin to truly define the differences in pathogenesis between fallopian tube and ovarian-derived
tumors. In doing so, we can hopefully improve early detection, treatment, and outcome.
The origins of high-grade serous ovarian
carcinoma
Ovariancanceriscurrentlythefifthleadingcauseofcancer
mortality among American women, responsible for
13,850 deaths in 2010. Its mortality rate is disproportio-
nately high because it typically goes undetected until
patients present with late-stage metastatic disease. Worse
still, current screening tools are largely ineffective, making
early detection difficult. Currently the standard care for
ovarian cancer patients is cytoreductive surgery followed
by platinum-taxane chemotherapy, and although most
tumors respond to drug treatment, chemoresistant disease
typically recurs, resulting in a 5-year survival rate of ~30%




grade serous ovarian carcinoma is our poor understand-
ing of its pathogenesis, and this includes uncertainty
surrounding its site of origin. Traditionally, the ovary was
thought to be the primary site of high-grade serous
ovarian carcinoma tumorigenesis and therefore imaging-
based screening techniques have focused on detecting
changes in ovary size and shape. However, recent studies
indicatethatmanyof the high-grade serous tumorsin the
pelvis actually arise from fallopian tube fimbria (or
possibly the fallopian tube-peritoneal junction) and
subsequently metastasize to the ovary [1-7] (figure 1).
Figure 2 illustrates the sequence of morphological events
described in the fallopian tube that culminate in the
development of serous carcinoma (Figure 2). The fact
that we may have been looking for early lesions in the
wrong anatomical location mayexplain why so few high-
grade serous ovarian carcinoma tumors have been
detected at early stage. Herein we will use the term
high-grade pelvic serous carcinoma (HGPSC) to account
for their possible extra-ovarian origin. The rarity of
finding early high-grade serous tumors has also made it
difficult to study pre-malignant and early-stage lesions
that may shed light on the pathogenesis of this disease.
A better understanding of the cell of origin should help
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intervention.
Elucidating the pathogenesis of high-grade
serous carcinoma
Although the genetics of early-stage HGPSC remain ill-
defined, the genetics of late-stage tumors have recently
been characterized in detail by large-scale integrated
genomic analyses conducted by the Cancer Genome Atlas
Research Network (CGARN), the Australian Ovarian
CancerStudy(AOCS),andtheOvarianCancerAssociation
Consortium (OCAC) [8-14]. These analyses, as well as
earlier smaller scale studies, reveal that high-grade serous
tumors are genetically distinct and generally not derived
from lower-grade ovarian carcinomas [15-17]. Low-grade
ovarian tumors, including low-grade serous, mucinous,
and endometrioid carcinomas, are characterized by a
spectrumofmutationsaffectinggrowthanddifferentiation
pathways. In stark contrast, HGPSCs typically harbor TP53
mutations and deficiencies in homologous recombination
repair, resulting in severe genomic instability, evidenced
by extensive DNA copy number changes [8, 18-21]. These
revelations, however, have generated more questions than
answers. For example, does the unique genetic profile of
HGPSC result from the tumor cell originating outside the
ovary? Or, can HGPSC arise from epithelial cells of either
the ovary or fallopian tube? Among the many chromoso-
mal aberrations observed in HGPSC, which genomic
alterations initiate and/or drive tumor progression? And
perhaps most importantly, which genetic aberrations are
required for high-grade serous tumor maintenance and
therefore represent targets for therapeutic intervention? To
answer these questions it is essential that we develop high-
fidelity experimental models with which to study the
transformation of fallopian tube epithelial cells. In order
for these models to be useful, however, it is important that
they recapitulate normal biology and can produce tumors
that exemplify not only the phenotype of human HGPSC
but also its underlying genomic complexity. Recently,
significant progress has been made in the development of
fallopian tube epithelium-based HGPSC models. Herein





The “ex vivo” model is a primary cell culture system in
which human epithelial cells are isolated from a fresh
sample of normal fallopian tube and used to reconstruct
an intact fallopian tube epithelium outside of the body
[22]. This sophisticated model is based upon one
previously developed to study bronchial airway epithe-
lium [23]. Primary ciliated and secretory cells, the two
cell types comprising fallopian tube epithelium, are
seeded onto a porous transwell cell culture membrane.
Remarkably, when seeded onto this membrane, the cells
assemble in an organized fashion, assuming their natural
orientation, architecture, polarity, extracellular features,
and biological functions, including motile cilia (ciliated
cells) and protein secretions (secretory cells) (Figure 3).
The ex-vivo model is viable for several weeks and is an
ideal system for studying normal fallopian tube epithe-
lium biology [24]. It can also be used to examine cellular
responses to environmental stress, mechanical damage,
DNA damage, cytokines, or inflammatory elements.
For example, this model has been used to show that
fallopian tube epithelial secretory cells exhibit delayed
DNA damage response kinetics, compared to neighbor-
ing ciliated cells, following genotoxic insult [22],
suggesting that the former cells may be susceptible to
accumulating additional DNA damage that could lead to
mutations with each subsequent round of injury. Despite
the authenticity of the ex vivo model, it is somewhat
limited by its small scale and requires a regular supply
of primary fallopian tube tissue from which to isolate
cells.
Figure 1. Emergence of serous carcinoma from the fallopian tube
and spread to adjacent ovarian surface
Emerging data suggest that many high-grade serous carcinomas (bottom
inset) emerge from secretory cells (top inset) in the fimbriated end of the
fallopian tube and spread to the ovarian surface epithelium where the bulk
of the tumor resides.
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To study normal fallopian tube epithelium on a larger
scale it is necessary to generate primary cell lines. Like
most primary human cells, cells of the fallopian tube
epithelium inevitably undergo growth arrest and rep-
licative senescence in vitro and therefore must be immor-
talized for long-term culture. Immortal human ovarian
surface epithelial cultures were first established over
15 years ago [25, 26] and have been widely used to study
biology and cellular transformation. However, immor-
talization of human fallopian tube epithelial cells has
only recently been reported [27] and therefore parallel
studies involving these cells have lagged behind.
Methods to isolate and culture primary fallopian tube
epithelial secretory cells, the presumptive cell of origin of
many HGPSC, from fresh samples of normal human
fallopian tube have now been published, demonstrating
that they can be immortalized by forced expression of
telomerase (hTERT) combined with dual targeting of the
p53 and pRb pathways.
Transformed human secretory cells
Integrated genomic analyses of HGPSC [8-14] have
identified hundreds of novel candidate oncogenes and
tumor suppressors potentially involved in HGPSC
tumorigenesis. Due to the extreme genomic complexity
of these tumors, however, it is impossible to deduce
which genetic alterations are most relevant to
the processes of cell transformation, tumor progression,
and tumor maintenance, respectively. Recently, large-
scale siRNA screening has been carried out to identify
genes whose amplification or expression is critical for
ovarian tumor cell survival and may be promising
therapeutic targets [28]. However, analysis of late-stage
tumors alone does not provide a comprehensive under-
standing of HGPSC pathogenesis; we must also identify
the genetic events involved in tumor initiation and early-
stage progression. One approach to assessing the roles of
candidate genes in these processes is to test their ability
to induce malignant phenotypes in vitro. It is important
that such studies be conducted using non-transformed
cells with relatively stable genomes, such as immortal
fallopian tube epithelial secretory cells. This approach
allows one to systematically evaluate the effects of
individual genetic alterations on a normal genetic back-
ground and to engineer malignant cells of various geno-
types from the same patient sample. Once transformed
cell cultures are established in vitro, they are xenografted
into mice to assess their tumorigenicity. Using this system,
our group recently demonstrated that immortal fallopian
tube epithelial secretory cells harboring hTERT, p53, pRb,
and PP2A dysfunctions are transformed by additional
expression of c-Myc or oncogenic Ras [27]. Upon injection
into immunocompromised mice, both c-Myc- and Ras-
transformed fallopian tube cells gave rise to disseminated
tumors that metastasized throughout the peritoneal cavity,
Figure 2. Morphologic development of high grade serous carcinoma from the fallopian tube
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The spectrum of fallopian tube epithelial transformation ranges from normal epithelium with ciliated and secretory cells, through the non-proliferative
‘p53 signature’ which is characterized by mutations in TP53 and wide-spread DNA damage, to tubal intraepithelial carcinoma (TIC), and eventually,
invasive serous carcinoma. Exfoliation of malignant cells is likely to be an early event. This model suggests that most high-grade pelvic serous carcinomas
originate from the fallopian tube fimbria, the region of the fallopian tube closest to the ovary.
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tumors were high-grade carcinomas with a Müllerian
immunophenotype, evidenced by Pax8, WT-1, and CK-7
immunohistochemistry positivity, and they expressed the
high-grade serous ovarian carcinoma serum biomarkers
CA-125 and HE-4, validating that they were indeed serous
carcinomas. Array comparative genomic hybridization
analysis of tumor tissue revealed widespread DNA copy
number changes, indicative of genomic instability and
highly reminiscent of the pattern seen in human HGPSC
[8-14]. Our system represents the first experimental model
of human HGPSC and provides a framework for future
studiesinvolving humanfallopiantubeepithelialsecretory
celltransformation.Inthefuture,thismodelcanbeusedto
generate high-grade serous tumors with clinically relevant
genetic alterations, such as TP53 mutations, BRCA1
dysfunction,andCyclinEoverexpression.Thesealterations
represent the few known early events of fallopian tube
tumorigenesis, and such a system should allow us to
elucidate their roles.
Transgenic mouse models
Several transgenic mouse models of ovarian cancer have
been developed over the past 10 years, all based on
transformation of ovarian surface epithelial cells.
Although considerable progress has been made, these
models have not fully recapitulated the complexity of
HGPSC. It is critical that a transgenic mouse model of
fallopian tube epithelium-derived cancer be generated to
complement existing ovarian surface epithelial-based
Figure 3. Ex vivo fallopian tube culture system
Fallopian tube epithelium is enzymatically dissociated from surgical samples and seeded onto porous transwell filters. The epithelial cells expandt o
form an epithelial monolayer that faithfully recapitulates the in vivo epithelium, as demonstrated by morphological (the bottom panel is a hematoxylin and
eosin stain of a filter removed for microscopic analysis), ultrastructural, immunophenotypic, and biological analyses.
Page 4 of 7
(page number not for citation purposes)
F1000 Medicine Reports 2011, 3:22 http://f1000.com/reports/m/3/22systems. Unlike ovarian surface epithelial cells, which
have no true tissue-specific gene promoters, fallopian
tube epithelium secretory cells express highly specific
lineage-dependent transcription factors such as Pax8,
which may direct transgene expression. Among the most
important genes to target in future mouse models will be
BRCA1 and BRCA2, the germline mutations linked to
familial ovarian and breast cancer, and TP53, which is
mutated in nearly 100% of HGPSC cases. Transgenic
mouse models of fallopian tube epithelium-derived
HGPSC are currently in development.
Data obtained from the experimental systems described
above, when combined with analyses of clinical speci-
mens representing the morphologic continuum from
normal fallopian tube epithelium to early tubal carcino-
mas and then to invasive HGPSC, will allow us to define
the genetic events leading to fallopian tube epithelium
tumorigenesis and thus significantly advance our under-
standing of HGPSC pathogenesis.
Translational impact
Insight gained from fallopian tube epithelium-derived
models of HGPSC will have a significant translational
impact in several key areas including risk reduction, early
detection, and treatment.
Epidemiological studies have long indicated that inces-
sant ovulation is a major HGPSC risk factor. The
mechanisms by which ovulatory events contribute to
tubal epithelial transformation are unknown but it is
hypothesized that follicular rupture during ovulation
produces an inflammatory microenvironment contain-
ing cytokines and free radicals that may inflict genotoxic
damage on nearby cells. Both transgenic mouse models
and ex vivo fallopian tube epithelium cultures will be
instrumental in exploring the contribution of ovulation
and its associated inflammatory factors to fallopian tube
epitheliumtumorigenesis.Transgenicmousemodelswill
also be key in understanding how germline mutations in
BRCA1 or BRCA2 genes confer increased risk of HGPSC
and determining whether removal of fallopian tubes
alone is sufficient to eliminate increased risk, as has been
recently proposed [29].
To reduce the HGPSC mortality rate, it is also imperative
that effective screening tools be developed. The ability to
screen for early lesionsin the fallopiantubeusing imaging
techniques presents a major challenge, as these lesions are
extremely small and may shed malignant cells into the
peritoneal cavity even at a pre-invasive stage. Therefore,
serum biomarker testing remains an optimal means of
early detection, since biomarker levels correlate with total
tumor mass, regardless of where the tumor cells reside.
Clinically used ovarian cancer biomarkers, CA-125 and
HE4,are notsensitive enough todetect early-stageHGPSC
and novel biomarkers with higher sensitivity must be
identified. Both transgenic mice and human xenograft
models of fallopian tube epithelium-derived HGPSC will
be critical tools for serum biomarker testing.
Lastly, in order to develop more effective therapies, it is
imperative that we utilize high-fidelity HGPSC models
for pre-clinical testing. Now that we are gaining
comprehensive genetic data from molecular analyses of
HGPSC, therapeutic discovery efforts can be focused on
targeting the genetic defects that uniquely characterize
HGPSC, for example drugs that exploit defective DNA
repair pathways and p53 dysfunction. Such novel
therapies may be tested on both murine and human-
derived tumors generated by transgenic mice and human
xenograft models of HGPSC, respectively.
Conclusion
A great deal of progress has been made in recent years
towards understanding the pathogenesis of both ovarian
and fallopiantube-derivedpelvicserouscarcinomas. With
the recent development of fallopian tube epithelium-
based experimental models, we can now begin to truly
define the differences between fallopian tube epithelium
and ovarian surface epithelium-derived tumors as they
relate to pathogenesis, biomarker expression, and res-
ponsetotreatment.Indoingso,wecanhopefullyimprove
early detection, treatment, and outcome for women with
ovarian cancer, in particular, HGPSC.
Abbreviation
HGPSC, High grade pelvic serous carcinoma.
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